FGFR2 and neoplasm: In clinical trials, a 6-fold copy number of FGFR1 and a 4-fold copy number of FGFR2 have been used as inclusion criteria for an expected high FGFR expression status, and these patients typically showed responses to FGFRi treatment as indicated by decreased tumor growth [9, 21].